Gadobutrol

Prostate Adenocarcinoma

Mayo ClinicSmall moleculePhase 3Dormant

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 73/ 100

Competitive context

89 Active assets in the Prostate Adenocarcinoma cohort.

Asset / Sponsor	Phase	Rating
Docetaxel Instituto do Cancer do Estado de São Paulo	Phase 3	BBB
Nilutamide SWOG Cancer Research Network	Phase 3	BB
Cyclophosphamide Beijing Biotech	Phase 2	BB
Degarelix Canadian Cancer Trials Group	Phase 3	BB
Prednisone Mayo Clinic	Phase 3	BB

View all 50 →

Same molecule, other indications

Gadobutrol is also rated in:

cognitive disorderActive

BB

Indicative · Phase 4

65 / 100

carotid stenosisDormant

BB

Indicative · Phase 3

64 / 100

breast cancerActive

B

Indicative · Phase 3

58 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.